In esophagal, colo-rectal, and prostate carcinomas, and gliomas, promoter methylation is the main mechanism of ECRG4 silencing, and treatment with demethylating agents restore gene expression [7]. This evidence concerns the gene ECRG4 and prostate carcinoma.